Show simple item record

dc.contributor.authorMeltzer, Eli
dc.contributor.authorRatner, Paul
dc.contributor.authorBachert, Claus
dc.contributor.authorCarr, Warner
dc.contributor.authorBerger, William
dc.contributor.authorCanonica, G. Walter
dc.contributor.authorHadley, James
dc.contributor.authorLieberman, Phil
dc.contributor.authorHampel, Frank C.
dc.contributor.authorMullol, Joaquim
dc.contributor.authorMunzel, Ullrich
dc.contributor.authorPrice, David
dc.contributor.authorScadding, Glenis
dc.contributor.authorVirchow, J. Christian
dc.contributor.authorWahn, Ulrich
dc.contributor.authorMurray, Ruth
dc.contributor.authorBousquet, Jean
dc.date.accessioned2020-06-16T10:45:01Z
dc.date.available2020-06-16T10:45:01Z
dc.date.issued2013-07
dc.identifier.citationMeltzer , E , Ratner , P , Bachert , C , Carr , W , Berger , W , Canonica , G W , Hadley , J , Lieberman , P , Hampel , F C , Mullol , J , Munzel , U , Price , D , Scadding , G , Virchow , J C , Wahn , U , Murray , R & Bousquet , J 2013 , ' Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis ' , International Archives of Allergy and Immunology , vol. 161 , no. 4 , pp. 369-377 . https://doi.org/10.1159/000351404en
dc.identifier.issn1018-2438
dc.identifier.otherPURE: 171119739
dc.identifier.otherPURE UUID: b032e894-32e6-4db5-918f-9e59dd7eb949
dc.identifier.otherScopus: 84877679580
dc.identifier.urihttps://hdl.handle.net/2164/14506
dc.descriptionAcknowledgements This study was funded by MedaPharma.en
dc.format.extent9
dc.language.isoeng
dc.relation.ispartofInternational Archives of Allergy and Immunologyen
dc.rights© 2013 S. Karger AG, Basel. This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercialNoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online version of the article only. Distribution for non-commercial purposes only https://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectAllergic rhinitisen
dc.subjectAzelastineen
dc.subjectFluticasoneen
dc.subjectMP29-02en
dc.subjectResponder analysisen
dc.subjectSevere chronic upper airway diseaseen
dc.subjectR Medicine (General)en
dc.subject.lccR1en
dc.titleClinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysisen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1159/000351404


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record